Verition Fund Management
RLAY icon

Verition Fund Management’s Relay Therapeutics RLAY Stock Holding History

Verition Fund Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Buy
+158,017
New +$2.29M 0.02% 912
2025
Q3 		– Sell
-290,599
Closed -$1.01M – 3967
2025
Q2 		$1.01M Buy
290,599
+151,355
+109% +$450K ﹤0.01% 2472
2025
Q1 		$365K Buy
139,244
+48,770
+54% +$191K ﹤0.01% 2767
2024
Q4 		$373K Buy
90,474
+14,335
+19% +$78K ﹤0.01% 2652
2024
Q3 		$539K Buy
76,139
+62,320
+451% +$466K ﹤0.01% 2279
2024
Q2 		$90.1K Sell
13,819
-5,575
-29% -$38.1K ﹤0.01% 2740
2024
Q1 		$161K Buy
19,394
+3,224
+20% +$31.5K ﹤0.01% 2533
2023
Q4 		$178K Sell
16,170
-42,655
-73% -$360K ﹤0.01% 2067
2023
Q3 		$495K Buy
58,825
+24,387
+71% +$262K 0.01% 1442
2023
Q2 		$433K Buy
+34,438
New +$428K 0.01% 1317

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Verition Fund Management's RLAY Position: Q2 2026 in Review

Verition Fund Management opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 158,017 shares worth $2.96M. The stake represents 0.02% of the portfolio and ranks #912 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in RLAY as recently as Q2 2025.

Verition Fund Management first reported a position in RLAY in Q2 2023 and has held it in 10 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Verition Fund Management held 158,017 shares of Relay Therapeutics worth $2.96M as of Q2 2026.
  • Relay Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Relay Therapeutics made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #912 holding.
  • Verition Fund Management first reported a position in Relay Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.